2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV) (Part 1 - small molecules, peptides and small molecule biomarkers by LCMS).

The 2016 10th Workshop on Recent Issues in Bioanalysis (10th WRIB) took place in Orlando, Florida with participation of close to 700 professionals from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizations, and regulatory agencies worldwide. WRIB was once again a 5-day, weeklong event - A Full Immersion Week of Bioanalysis including Biomarkers and Immunogenicity. As usual, it was specifically designed to facilitate sharing, reviewing, discussing and agreeing on approaches to address the most current issues of interest including both small and large molecule analysis involving LCMS, hybrid LBA/LCMS, and LBA approaches, with the focus on biomarkers and immunogenicity. This 2016 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop, and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. This white paper is published in 3 parts due to length. This part (Part 1) discusses the recommendations for small molecules, peptides and small molecule biomarkers by LCMS. Part 2 (Hybrid LBA/LCMS and regulatory inputs from major global health authorities) and Part 3 (large molecule bioanalysis using LBA, biomarkers and immunogenicity) will be published in the Bioanalysis journal, issue 23.

[1]  Hollie H. Barton,et al.  Small Molecule Specific Run Acceptance, Specific Assay Operation, and Chromatographic Run Quality Assessment: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Teams , 2014, The AAPS Journal.

[2]  Stephanie Cape,et al.  7th GCC Insights: incurred samples use; fit-for-purpose validation, solution stability, electronic laboratory notebook and hyperlipidemic matrix testing. , 2014, Bioanalysis.

[3]  Stephanie Cape,et al.  9th GCC closed forum: CAPA in regulated bioanalysis; method robustness, biosimilars, preclinical method validation, endogenous biomarkers, whole blood stability, regulatory audit experiences and electronic laboratory notebooks. , 2016, Bioanalysis.

[4]  Lindsay King,et al.  2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 - LBA and immunogenicity). , 2014, Bioanalysis.

[5]  Renuka Pillutla,et al.  2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3--LBA, biomarkers and immunogenicity). , 2015, Bioanalysis.

[6]  Lindsay King,et al.  2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 - hybrid LBA/LCMS, ELN & regulatory agencies' input). , 2014, Bioanalysis.

[7]  Stacy Ho,et al.  2011 White paper on recent issues in bioanalysis and regulatory findings from audits and inspections. , 2011, Bioanalysis.

[8]  Xia Yin,et al.  2009 White Paper on recent issues in regulated bioanalysis from the 3rd Calibration and Validation Group Workshop. , 2010, Bioanalysis.

[9]  Fabio Garofolo,et al.  The 2nd Calibration and Validation Group workshop on recent issues in good laboratory practice bioanalysis. , 2009, Bioanalysis.

[10]  R. Boulieu,et al.  Modified high-performance liquid chromatographic method for the determination of ganciclovir in plasma from patients with severe renal impairment. , 1991, Journal of chromatography.

[11]  Li Xue,et al.  2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 1--small molecules by LCMS). , 2014, Bioanalysis.

[12]  Donald G Robertson,et al.  The utility of stable isotope labeled (SIL) analogues in the bioanalysis of endogenous compounds by LC-MS applied to the study of bile acids in a metabolomics assay. , 2016, Analytical biochemistry.

[13]  Neil Spooner,et al.  Quantitative bioanalysis of paracetamol in rats using volumetric absorptive microsampling (VAMS). , 2015, Journal of pharmaceutical and biomedical analysis.

[14]  Roger Hayes,et al.  8th GCC: consolidated feedback to US FDA on the 2013 draft FDA guidance on bioanalytical method validation. , 2014, Bioanalysis.

[15]  Roger Hayes,et al.  Recommendations on biomarker bioanalytical method validation by GCC. , 2012, Bioanalysis.

[16]  Stacy Ho,et al.  2013 White Paper on recent issues in bioanalysis: 'hybrid'--the best of LBA and LCMS. , 2013, Bioanalysis.

[17]  Eric Woolf,et al.  2010 white paper on recent issues in regulated bioanalysis & global harmonization of bioanalytical guidance. , 2010, Bioanalysis.

[18]  L. Cohen,et al.  Quantitation of endogenous analytes in biofluid without a true blank matrix. , 2003, Analytical chemistry.

[19]  Shuguang Ma,et al.  Data acquisition and data mining techniques for metabolite identification using LC coupled to high-resolution MS. , 2013, Bioanalysis.

[20]  Bradley L Ackermann,et al.  Surrogate matrix and surrogate analyte approaches for definitive quantitation of endogenous biomolecules. , 2012, Bioanalysis.

[21]  Viswanath Devanarayan,et al.  Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.

[22]  Roger Hayes,et al.  2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 1 - small molecules by LCMS). , 2015, Bioanalysis.

[23]  Timothy Olah,et al.  Strategy to improve the quantitative LC-MS analysis of molecular ions resistant to gas-phase collision induced dissociation: application to disulfide-rich cyclic peptides. , 2014, Analytical chemistry.

[24]  E. Woolf,et al.  Effect of disease state on ionization during bioanalysis of MK-7009, a selective HCV NS3/NS4 protease inhibitor, in human plasma and human Tween-treated urine by high-performance liquid chromatography with tandem mass spectrometric detection. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[25]  R. Allison,et al.  Sample collection and handling: getting accurate results. , 2007, The Veterinary clinics of North America. Small animal practice.

[26]  Kevin Bateman,et al.  Direct comparison of radioimmunoassay and LC-MS/MS for PK assessment of insulin glargine in clinical development. , 2014, Bioanalysis.

[27]  Christopher Evans,et al.  Modify on the fly: triple quad to high resolution in support of a dermal clinical study requiring an ultra low LLOQ. , 2016, Bioanalysis.

[28]  J. Vaught,et al.  Blood Collection, Shipment, Processing, and Storage , 2006, Cancer Epidemiology Biomarkers & Prevention.

[29]  Roberto Pontarolo,et al.  Uncovering previously undetected metabolites using modern bioanalytical tools. , 2015, Bioanalysis.

[30]  Kevin Bateman,et al.  2 Bioanalytical report writing , 2022 .

[31]  Surinder Kaur,et al.  2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 2 - hybrid LBA/LCMS and input from regulatory agencies). , 2015, Bioanalysis.

[32]  Steve Lowes,et al.  HRMS using a Q-Exactive series mass spectrometer for regulated quantitative bioanalysis: how, when, and why to implement. , 2016, Bioanalysis.

[33]  S. Bates,et al.  European Bioanalysis Forum recommendation on method establishment and bioanalysis of biomarkers in support of drug development. , 2012, Bioanalysis.